Santen and TRACON Pharmaceuticals announced the companies will discontinue the development of DE-122 for the treatment of wet age-related macular degeneration (wAMD) following the review of top-line data from the Phase 2a AVANTE clinical study. The study did not reach the primary endpoint.
The Phase 2a AVANTE clinical study is a randomized controlled trial that assessed visual acuity in wAMD patients following six monthly treatments with a combination of DE-122 and Lucentis or single agent Lucentis. Topline data indicated that DE-122 did not improve visual acuity when combined with Lucentis as compared to single agent Lucentis treatment, the primary endpoint of the trial.
Santen licensed the development rights to DE-122 in the ophthalmic field from TRACON in 2014.
DE-122 is the ophthalmic formulation of TRACON’s proprietary anti-endoglin antibody, TRC105. TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation.
About Wet AMD
Wet AMD is the leading cause of blindness in the elderly in the world and is caused by excessive growth and leakage of blood vessels at the back of the eye that leads to a chronic and often rapid loss of vision. Existing therapies for the disease are limited including treatment targeting the VEGF pathway.